Akebia Therapeutics

267 articles with Akebia Therapeutics

• Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat

  6/4/2021

  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that it has entered into an exclusive, global license agreement with Akebia Therapeutics, Inc., a leading biopharmaceutical company focused on kidney disease, for the development and commercialization of praliciguat, an oral sGC stimulator.

• Akebia Therapeutics Announces Presentations at ERA-EDTA Virtual Congress 2021

  6/3/2021

  Akebia Therapeutics, Inc.  (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced presentations of data from the global Phase 3 program for vadadustat at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Virtual Conference

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 02, 2021

  6/2/2021

  Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 15 newly-hired employees options to purchase an aggregate of 121,000 shares of Akebia's common stock on May 28, 2021, as inducements material to each such employee's entering into employment with Akebia.

• Akebia and Otsuka Announce FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis

  6/1/2021

  Akebia Therapeutics, Inc. and its collaborator, Otsuka Pharmaceutical Co., Ltd., announced that the U.S. Food and Drug Administration accepted for filing the New Drug Application for vadadustat for the treatment of anemia due to chronic kidney disease in both adult patients on dialysis and adult patients not on dialysis.

• Akebia Reports First Quarter 2021 Financial Results and Highlights Recent Company Milestones

  5/10/2021

  - Vadadustat New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) - Results of global Phase 3 programs for vadadustat published in New England Journal of Medicine - Conference call today at 9:00 a.m. ET

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 04, 2021

  5/4/2021

  Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 9 newly-hired employees options to purchase an aggregate of 197,200 shares of Akebia's common stock on April 30, 2021, as inducements material to each such employee's entering into employment with Akebia.

• New England Journal of Medicine Publishes Results of Global Phase 3 Clinical Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease

  4/28/2021

   Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the New England Journal of Medicine (NEJM) has published the results of the global Phase 3 clinical program of vadadustat for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis

• Akebia Therapeutics to Report First Quarter 2021 Financial Results and Discuss Recent Business Highlights

  4/28/2021

  Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the first quarter ended March 31, 2021 , on Monday, May 10, 2021 before the opening of the financial markets.

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 02, 2021

  4/2/2021

  Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 19 newly-hired employees options to purchase an aggregate of 131,000 shares of Akebia's common stock on March 31, 2021, as inducements material to each such employee's entering into employment with Akebia.

• Otsuka and Akebia Announce Submission of New Drug Application to the FDA for Approval of Akebia’s Vadadustat

  3/30/2021

  Indications for renal anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis-dependent adult patients

• Akebia Submits New Drug Application (NDA) to the FDA for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis

  3/30/2021

  Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for vadadustat, Akebia's investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for the treatment of anemia due to chronic kidney disease in both adult patients on dialysis and adult patients not on dialysis.

• Akebia Therapeutics Announces Poster Presentations and Educational Symposium at National Kidney Foundation 2021 Virtual Spring Clinical Meetings

  3/25/2021

  Akebia Therapeutics, Inc.  (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the National Kidney Foundation 2021 Spring Clinical Meetings (NKF SCM21), which takes place virtually April 6-10, 2021 .

• Akebia Therapeutics Announces Approval for Additional Indication of Riona® (ferric citrate hydrate) for the Treatment of Iron Deficiency Anemia in Adult Patients in Japan

  3/24/2021

  Akebia Therapeutics, Inc. (Nasdaq: AKBA),  today announced that its collaboration partner, Japan Tobacco Inc. (JT), received approval from the Pharmaceuticals and Medical Devices Agency (PMDA) for an additional indication for Riona® Tablets 250mg (Riona) (generic name in Japan: ferric citrate hydrate) to treat adult patients with iron deficiency anemia (IDA) in Japan.

• Akebia Therapeutics Celebrates World Kidney Day and National Kidney Month

  3/11/2021

  Company Initiates Campaign to Honor Patients and Promote Awareness of Kidney Disease

• Akebia Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference

  3/2/2021

  Akebia Therapeutics, Inc.  (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler , Chief Executive Officer of Akebia, will participate in a fireside chat at the H.C. Wainwright Global Life Sciences Conference

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 02, 2021

  3/2/2021

  Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly-hired employees options to purchase an aggregate of 44,000 shares of Akebia's common stock on February 26, 2021, as inducements material to each such employee's entering into employment with Akebia.

• Akebia Therapeutics Appoints LeAnne M. Zumwalt, Dialysis Industry Leader, to Board of Directors

  2/18/2021

  Akebia Therapeutics, Inc. , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of LeAnne M. Zumwalt to its Board of Directors, effective February 16, 2021 .

• Akebia Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Discuss Recent Business Highlights

  2/8/2021

  Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the fourth quarter and full-year 2020 ended December 31, 2020, on Thursday, February 25, 2021, before the opening of the financial markets.

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 02, 2021

  2/2/2021

  Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 19 newly-hired employees options to purchase an aggregate of 161,000 shares of Akebia's common stock on January 29, 2021, as inducements material to each such employee's entering into employment with Akebia.

• Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference

  1/6/2021

  Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler , President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect 2021 C